# PEAK-1 (NCT07011719)

> Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: casdatifan plus cabozantinib
- Indication: advanced clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07011719
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Arcus Biosciences, Inc.
- Conditions: Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma
- Interventions: Casdatifan; Cabozantinib; Placebo
- Enrollment: 720
- Primary outcome: Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1

## Questions raised in the commentary

_Automated from the 36 newest of 49 indexed sources (Oct 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether adding casdatifan improves outcomes beyond cabozantinib
- How anemia and hypoxia may affect tolerability of casdatifan plus cabozantinib
- How PEAK-1 may shape treatment sequencing after immunotherapy

Also discussed: other HIF-2α inhibitor combinations.

## Indexed commentary on PEAK-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 36
- YouTube: 11
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=peak-1-nct07011719

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07011719", "email": "<work email>"}; the inbox owner confirms by the emailed link.